Pharmaceutical composition comprising cdk inhibitor and id2 activator for prevention or treatment of bladder cancer

Abstract

The present invention relates to a pharmaceutical composition including a CDK inhibitor and an ID2 activator for the prevention or treatment of bladder cancer, wherein based on the finding that: among CDK1-TFCP2L1 pathway targets associated with urothelial differentiation in bladder cancer cells, ID2 is a factor significantly correlating with the tumor grade of bladder cancer; an ID2 activator exhibits a therapeutic effect on bladder cancer; and the combined administration of CDK1 inhibitor and ID2 activator induces apoptosis of bladder cancer cells and significantly suppresses the invasiveness of cancer cells, compared to administration thereof alone, thereby exhibiting a therapeutic effect of remarkably suppressing the size and progression of bladder cancer, a composition comprising a CDK inhibitor and an ID2 activator and a method for combined administration thereof are provided as novel therapeutic means for the prevention or treatment of bladder cancer.

Dependencies are inferred from the claim text.